The going-concern disclosure signals high risk of equity dilution or restructuring. Monitor for completion of the referenced merger and financing — failure to close would likely force operational shutdown or distressed sale.
Price Chart
Executive Summary
Obsidian Therapeutics filed an 8-K with a lease amendment and a risk factors exhibit that discloses a net loss of $100.6M for 2025, cash of $80.5M, and substantial doubt about going concern. The company remains pre-revenue and clinical-stage, with lead candidate OBX-115 in Phase 2. The financial deterioration and going concern warning are strongly negative.
Key Facts
- Net loss of $100.6 million for the year ended December 31, 2025
- Cash, cash equivalents, and marketable securities of $80.5 million as of December 31, 2025
- Independent auditor included a going concern emphasis in the 2025 annual report
- No products approved and no revenue generated to date
- Lead product candidate OBX-115 in Phase 2 for advanced melanoma and Phase 1 for NSCLC
- Lease extended through January 31, 2027 with base rent escalation
- Company pursuing mergers and concurrent financing to fund operations
Financial Impact
Net loss of $100.6M in 2025 (vs $83.1M in 2024); cash burn rate suggesting runway only into Q3 2026 even with merger proceeds
Risk Factors
- Going concern risk — may not have sufficient capital to continue operations beyond Q3 2026
- Clinical trial failure risk for OBX-115
- Dilution risk from planned mergers and concurrent financing
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-330810 |
| Document: d309963dex992.htm | 0001193125-26-330810 |
| 8-K Data (Synthetic) | 0001193125-26-330810 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 22d ago | SC 13G | $13.22 | awaiting T+20 | — | $14.25 (+7.79%) |
Sep 10, 2026 6w ago | EFFECT | $17.16 $12.24 | ▼ −28.67% | ▼ −30.80% | $14.25 (−16.96%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.25 (−58.09%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.25 (−58.09%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.25 (−58.09%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.25 (−58.09%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.25 (−58.09%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.25 (−58.09%) |
Aug 3, 2026 12w ago | 8-K | $34.00 $17.04 | ▲ +49.88% | ▲ +48.64% | $14.25 (+58.09%) |
Jul 6, 2026 16w ago | EFFECT | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers